Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.

Therapeutic drug monitoring - 1 Oct 1999

Kovacs P, Edwards D J, Lalka D, Scheiwe W M, Stoeckel K

Abstract excerpt

The objectives of this multiple-dose study were to compare the performance of a new formulation of omeprazole (40 mg) with that of an established formulation and to assess the accuracy of CYP2C19 phenotyping during high-dose chronic administration. Twenty-eight healthy subjects were randomized (1:1) to receive 40 mg of either Gasec-40 Gastrocaps (Mepha) or Antra 40 (Astra) daily for 5 days. The pharmacokinetics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Anti-Ulcer Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aryl Hydrocarbon Hydroxylases

Share to Cross-Over Studies

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 Enzyme System

Share to Mixed Function Oxygenases

Share to Omeprazole

Source

Identifiers

PMID: 10519449
DOI: 10.1097/00007691-199910000-00006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High-dose omeprazole: use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping.PMID 10519449Read ↗

Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping.Semantic proximity Read ↗

Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity.Semantic proximity Read ↗

Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies.Semantic proximity Read ↗

Omeprazole disposition in children following single-dose administration.Semantic proximity Read ↗

Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.Semantic proximity Read ↗

CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection.Semantic proximity Read ↗

Optimal dose of omeprazole for CYP2C19 extensive metabolizers in anti-Helicobacter pylori therapy: pharmacokinetic considerations.Semantic proximity Read ↗

Pharmacokinetics and Bioequivalence of Two Formulations of Omeprazole and Sodiun bicarbonate powder, for suspension: A Randomized, Single-Dose, Two-Period, Two-Sequence Crossover Study in Healthy Chinese VolunteersSemantic proximity Read ↗

Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios.Semantic proximity Read ↗

Influence of CYP2C19 Polymorphisms on the Pharmacokinetics of Omeprazole in Elderly Subjects.Semantic proximity Read ↗

Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study.Semantic proximity Read ↗

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.